Download presentation
Presentation is loading. Please wait.
Published byHerbert Parsons Modified over 6 years ago
1
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation Christine E. Ryan, Aaron C. Logan, Andrew Rezvani, Manali Kamdar, Hideki Nakasone, Bita Sahaf, Joanne Otani, Katherine A. Kong, Mark Klinger, Malek Faham, Steven Coutre, David B. Miklos Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S307-S308 (February 2015) DOI: /j.bbmt Copyright © Terms and Conditions
2
Figure 1 (A) Percent reduction in LN size, reported as sum of the product of LN diameters (SPD), for 4 patients following ibrutinib initiation. (B) CLL MRD (as percent of WBCs) and blood donor CD3 chimerism for SPN3975 and(C) SPN3431. (D) B cells (excluding the CLL clone) as percent of total PBMC for SPN3975. (E) Total IgH molecules and unique IgH clone counts for SPN3975 at time points (D=day) post allo-HCT. Biology of Blood and Marrow Transplantation , S307-S308DOI: ( /j.bbmt ) Copyright © Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.